Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia.
Account Res. 2011 Jan;18(1):45-54. doi: 10.1080/08989621.2011.542683.
Journals are failing in their obligation to ensure that research is fairly represented to their readers, and must act decisively to retract fraudulent publications. Recent case reports have exposed how marketing objectives usurped scientific testing and compromised the credibility of academic medicine. But scant attention has been given to the role that journals play in this process, especially when evidence of research fraud fails to elicit corrective measures. Our experience with The Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) illustrates the nature of the problem. The now-infamous Study 329 of paroxetine in adolescent depression was negative for efficacy on all eight protocol-specified outcomes and positive for harm, but JAACAP published a report of this study that concluded that "paroxetine is generally well tolerated and effective for major depression in adolescents." The journal's editors not only failed to exercise critical judgment in accepting the article, but when shown evidence that the article misrepresented the science, refused either to convey this information to the medical community or to retract the article.
期刊未能履行其职责,确保研究能公正地呈现给读者,因此必须果断采取行动,撤回伪造的出版物。最近的案例报告揭示了营销目标如何篡夺科学测试,损害学术医学的可信度。但是,期刊在这个过程中所扮演的角色几乎没有得到关注,尤其是当研究欺诈的证据未能引发纠正措施时。我们在《美国儿童与青少年精神病学学会杂志》(JAACAP)的经验说明了这个问题的本质。现在臭名昭著的帕罗西汀治疗青少年抑郁症的研究 329 对所有八项方案规定的结果都没有疗效,反而有危害,但 JAACAP 发表了这份研究报告,得出的结论是“帕罗西汀通常在青少年重度抑郁症中耐受性良好且有效”。期刊的编辑不仅未能在接受这篇文章时进行批判性判断,而且当他们看到证据表明该文章歪曲了科学,他们拒绝向医学界传达这一信息,也拒绝撤回该文章。